{"gene":"SDHAF2","run_date":"2026-06-10T07:46:30","timeline":{"discoveries":[{"year":2009,"finding":"Yeast and human SDH5 (SDHAF2) physically interact with the catalytic subunit of succinate dehydrogenase (Sdh1/SDHA) and are required for flavination (covalent attachment of FAD cofactor) of Sdh1/SDHA and for SDH-dependent respiration.","method":"Yeast genetics, mitochondrial proteomics, interaction studies, SDH activity assays, in vivo flavination assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction demonstrated, functional SDH activity and flavination assays in both yeast and human systems, replicated by multiple subsequent studies","pmids":["19628817"],"is_preprint":false},{"year":2012,"finding":"NMR structure of yeast Sdh5 reveals a conserved surface region constituting a putative Sdh1-binding interface; point mutations in this region abolish covalent flavinylation of Sdh1. Sdh5 does not bind FAD in vitro, indicating it is not a simple FAD transporter.","method":"Solution NMR structure determination, site-directed mutagenesis, chemical shift perturbation measurements, in vivo flavinylation assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure plus mutagenesis and negative FAD-binding result in a single focused study","pmids":["23062074"],"is_preprint":false},{"year":2014,"finding":"SDH5/SDHAF2 (G78R disease mutant) is imported and processed normally into human mitochondria but is rapidly degraded by the mitochondrial protease LONM (LON protease). Wild-type SDH5 is protected from LONM-mediated degradation through stable interaction with SDHA; the G78R mutant fails to form a stable complex with SDHA and is therefore degraded.","method":"Import-chase analysis in isolated human mitochondria (HeLa cells), in vitro LON protease degradation assay, LONM siRNA depletion, Blue Native PAGE complex analysis, SDHA siRNA depletion","journal":"FASEB Journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (import assay, in vitro degradation, BN-PAGE, siRNA depletion) in a single focused study","pmids":["24414418"],"is_preprint":false},{"year":2016,"finding":"In vitro flavinylation of recombinant human apo-SDHA is completely dependent on added SDH5 (SDHAF2), with a pH optimum of 6.5. FAD interacts noncovalently with SDHA in the absence of SDH5, suggesting SDH5 facilitates the covalent attachment step.","method":"In vitro flavinylation assay using recombinant His-tagged human apo-SDHA immobilized on Ni-IMAC resin with purified SDH5 in chemically defined medium","journal":"Archives of Biochemistry and Biophysics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous in vitro reconstitution but single lab, single study","pmids":["27296776"],"is_preprint":false},{"year":2016,"finding":"In human breast cancer cells, SDHAF2/SDH5 is dispensable for SDHA flavination: CRISPR-Cas9 nickase-mediated SDHAF2 knockout breast cancer cells retain flavinated SDHA, fully assembled and functional complex II, and normal mitochondrial respiration, demonstrating a cell-type-specific alternative flavination mechanism.","method":"CRISPR-Cas9 nickase knockout, complex II activity assay, mitochondrial respiration assay, SDHA flavination assay","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean KO with multiple functional readouts but single lab; contradicts yeast/other findings, suggesting context-dependency","pmids":["27587393"],"is_preprint":false},{"year":2020,"finding":"X-ray crystal structure of human SDHA in complex with SDHAF2 reveals that a small-molecule dicarboxylate acts as an essential cofactor that works in synergy with SDHAF2 to reorient the flavin and capping domains of SDHA, reorganize the active site, and adjust the pKa of SDHA-R451 to support covalent FAD attachment. Disease-associated SDHA mutations affect distinct conformational states assigned to assembly vs. catalysis.","method":"X-ray crystallography of human SDHA–SDHAF2 complex, biochemical reconstitution, disease mutant analysis, identification of dicarboxylate cofactor","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with biochemical reconstitution and mutant analysis in a single rigorous study","pmids":["32887801"],"is_preprint":false},{"year":2024,"finding":"Drp1-mediated mitochondrial fission is required for mitochondrial translocation of SDHAF2 in skeletal muscle; knockdown of Drp1 reduces SDHAF2 mitochondrial import, leading to impaired complex II assembly and activity. Restoration of SDHAF2 in Drp1-KD myocytes normalizes complex II activity, lipid oxidation, and insulin sensitivity, placing SDHAF2 downstream of Drp1 in a mitochondrial morphology–metabolism axis.","method":"Drp1 knockdown in mouse muscle (in vivo), mitochondrial fractionation, complex II assembly and activity assays, Sdhaf2 rescue experiments in myocytes, metabolic phenotyping (fatty acid oxidation, insulin action)","journal":"Science Advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with rescue, multiple functional readouts; single lab","pmids":["38569044"],"is_preprint":false},{"year":2013,"finding":"Loss of SDH5 (SDHAF2) in lung cancer cells and mice initiates epithelial-mesenchymal transition (EMT), evidenced by repression of E-cadherin and upregulation of vimentin, and promotes lymph node metastasis in a human lung xenograft model. SDH5 modulates EMT by regulating the GSK-3β–β-catenin signaling pathway.","method":"SDH5 knockdown/knockout in lung cancer cell lines and mice, E-cadherin/vimentin expression, human xenograft-mouse metastasis model, GSK-3β/β-catenin pathway analysis","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD/KO with defined cellular and in vivo phenotypes plus pathway analysis; single lab","pmids":["23983127"],"is_preprint":false},{"year":2019,"finding":"SDH5 (SDHAF2) regulates PD-L1 expression in lung cancer via the GSK3β/β-catenin/ZEB1 signaling axis; SDH5 loss increases PD-L1 expression through this pathway.","method":"SDH5 overexpression/knockdown in lung cancer cells, PD-L1 expression analysis in vitro and patient tissues, pathway inhibitor experiments (GSK3β/β-catenin/ZEB1)","journal":"Oncoimmunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, signaling pathway correlation with limited mechanistic depth reported in abstract","pmids":["31741753"],"is_preprint":false},{"year":2019,"finding":"SDH5 (SDHAF2) depletion inhibits p53 degradation via the ubiquitin/proteasome pathway, promoting apoptosis and enhancing radiosensitivity in non-small cell lung cancer. SDH5 interaction with p53 was detected by immunoprecipitation and GST pulldown, and SDH5-dependent polyubiquitination of p53 was demonstrated by in vitro ubiquitination assay.","method":"SDH5 KO mice and human xenograft model, immunoprecipitation, GST pulldown, in vitro ubiquitination assay, apoptosis/DNA damage assays","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vitro ubiquitination assay plus pulldown and in vivo model; single lab, single study","pmids":["31588224"],"is_preprint":false},{"year":2010,"finding":"The SDHAF2 Gly78Arg (G78R) mutation is pathogenic for hereditary paraganglioma; identification of a second unrelated family with the same mutation confirms Gly78 as a critical residue for SDHAF2 function.","method":"Germline mutation analysis, haplotype analysis in familial paraganglioma kindreds","journal":"The Lancet Oncology","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — genetic evidence from two families confirms functional importance of Gly78, but no direct biochemical mechanism reported in this paper","pmids":["20071235"],"is_preprint":false},{"year":2017,"finding":"Loss of the entire maternal copy of chromosome 11 occurs in 89% of SDHAF2-related paragangliomas, always affecting the maternal allele, consistent with the parent-of-origin imprinting effect and providing a mechanistic basis for the paternal transmission requirement in SDHAF2 disease.","method":"FISH, microsatellite marker analysis, SNP array analysis, methylation analysis of imprinted DMRs (H19-DMR, KvDMR) in SDHAF2-related tumor specimens","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal genomic methods on tumor specimens; single study but mechanistically informative for imprinting mechanism","pmids":["28099933"],"is_preprint":false}],"current_model":"SDHAF2 (SDH5) is a mitochondrial assembly factor that physically interacts with the SDHA flavoprotein subunit of complex II; together with a dicarboxylate cofactor (as revealed by the crystal structure of the human SDHA–SDHAF2 complex), it reorients the SDHA active site and lowers the pKa of SDHA-R451 to enable covalent attachment of FAD—a process that can be fully reconstituted in vitro—while SDHAF2 itself is protected from LON protease degradation only when stably bound to SDHA, explaining why the disease-causing G78R mutant is rapidly turned over. Beyond its canonical assembly role, SDHAF2 has been reported to modulate GSK-3β/β-catenin signaling (affecting EMT and PD-L1 expression in lung cancer) and to regulate p53 stability, and its mitochondrial import depends on Drp1-mediated fission in skeletal muscle; maternal-allele loss of chromosome 11 underpins the parent-of-origin tumor risk conferred by SDHAF2 mutations."},"narrative":{"mechanistic_narrative":"SDHAF2 (SDH5) is a mitochondrial assembly factor for succinate dehydrogenase (complex II) that physically interacts with the catalytic flavoprotein subunit SDHA and is required for its covalent flavinylation and SDH-dependent respiration [PMID:19628817]. SDHAF2 does not itself bind FAD; instead, a conserved surface region forms the SDHA-binding interface, and mutations there abolish flavinylation, establishing SDHAF2 as a catalytic chaperone rather than a simple FAD transporter [PMID:23062074]. In vitro reconstitution shows that flavinylation of recombinant apo-SDHA is fully dependent on SDHAF2 with an acidic pH optimum, acting at the covalent attachment step [PMID:27296776], and the human SDHA–SDHAF2 crystal structure resolves the mechanism: a small-molecule dicarboxylate cofactor works in synergy with SDHAF2 to reorient the SDHA flavin and capping domains and adjust the pKa of SDHA-R451 to enable covalent FAD attachment [PMID:32887801]. SDHAF2 stability is coupled to this interaction—it is protected from LON protease degradation only when stably bound to SDHA, explaining the rapid turnover of the disease-associated G78R mutant, which fails to form a stable complex [PMID:24414418]. This role is context-dependent: SDHAF2 is dispensable for SDHA flavination in certain breast cancer cells, which retain functional complex II via an alternative mechanism [PMID:27587393]. Germline SDHAF2 mutation (G78R) causes hereditary paraganglioma, with the parent-of-origin tumor risk explained by maternal-allele loss of chromosome 11 in tumors [PMID:20071235, PMID:28099933]. Beyond assembly, reported extramitochondrial functions include modulation of GSK-3β/β-catenin signaling driving EMT and metastasis [PMID:23983127] and regulation of p53 stability via the ubiquitin/proteasome pathway [PMID:31588224].","teleology":[{"year":2009,"claim":"Established the existence and core function of SDHAF2 by showing it is a dedicated interactor of the SDH catalytic subunit required for FAD attachment, defining a previously unrecognized assembly step for complex II.","evidence":"Yeast genetics, mitochondrial proteomics, and in vivo flavination/SDH activity assays in yeast and human systems","pmids":["19628817"],"confidence":"High","gaps":["Did not resolve whether SDHAF2 acts catalytically or as an FAD carrier","No structural basis for the SDHA interface","Conservation of mechanism across cell types untested"]},{"year":2012,"claim":"Defined SDHAF2 as a catalytic chaperone rather than an FAD transporter by mapping the SDHA-binding surface and demonstrating it does not bind FAD itself.","evidence":"Solution NMR structure of yeast Sdh5, chemical shift perturbation, site-directed mutagenesis, and in vivo flavinylation assays","pmids":["23062074"],"confidence":"High","gaps":["Did not show how SDHAF2 promotes covalent attachment mechanistically","Human SDHAF2 structure not determined here","No co-structure with SDHA"]},{"year":2010,"claim":"Linked SDHAF2 to human disease by establishing the G78R mutation as pathogenic for hereditary paraganglioma, identifying Gly78 as a functionally critical residue.","evidence":"Germline mutation and haplotype analysis in two familial paraganglioma kindreds","pmids":["20071235"],"confidence":"Low","gaps":["No direct biochemical mechanism for G78R reported in this study","Parent-of-origin transmission unexplained at the molecular level","Tissue specificity of tumorigenesis unaddressed"]},{"year":2014,"claim":"Explained why the G78R mutant is loss-of-function by showing SDHAF2 stability depends on SDHA binding, with unbound or mutant protein cleared by LON protease.","evidence":"Import-chase in isolated human mitochondria, in vitro LON degradation, BN-PAGE, and LONM/SDHA siRNA depletion","pmids":["24414418"],"confidence":"High","gaps":["Structural reason for G78R destabilization not defined","Did not address whether LON regulates SDHAF2 levels physiologically","In vivo relevance to paraganglioma tissue untested"]},{"year":2016,"claim":"Demonstrated by full in vitro reconstitution that SDHAF2 is strictly required for covalent flavinylation of apo-SDHA, acting at the attachment step under acidic conditions.","evidence":"In vitro flavinylation of recombinant immobilized apo-SDHA with purified SDH5 in defined medium","pmids":["27296776"],"confidence":"Medium","gaps":["Single lab reconstitution","Did not identify the chemical role of accessory cofactors","Catalytic mechanism inferred, not visualized"]},{"year":2016,"claim":"Revealed context dependence of SDHAF2 by showing it is dispensable for SDHA flavination in breast cancer cells, implying an alternative flavination route.","evidence":"CRISPR-Cas9 nickase knockout with complex II activity, respiration, and SDHA flavination assays","pmids":["27587393"],"confidence":"Medium","gaps":["Identity of the alternative flavination mechanism unknown","Single cell-type/single lab observation","Reconciliation with strict in vitro dependence unresolved"]},{"year":2020,"claim":"Resolved the molecular mechanism of SDHAF2-assisted flavinylation by capturing the human SDHA–SDHAF2 complex and identifying a dicarboxylate cofactor that, with SDHAF2, reorganizes the active site and tunes SDHA-R451 pKa.","evidence":"X-ray crystallography of the human SDHA–SDHAF2 complex with biochemical reconstitution and disease-mutant analysis","pmids":["32887801"],"confidence":"High","gaps":["Dynamics of cofactor entry/exit not captured","Does not explain alternative flavination in some cancer cells","Extramitochondrial functions not addressed"]},{"year":2017,"claim":"Provided the molecular basis for parent-of-origin tumor risk by showing maternal chromosome 11 loss in most SDHAF2-related paragangliomas, consistent with imprinting.","evidence":"FISH, microsatellite and SNP array analysis, and DMR methylation analysis of tumor specimens","pmids":["28099933"],"confidence":"Medium","gaps":["Mechanism linking SDH loss to paraganglioma initiation not defined","Single study cohort","Does not establish the tumor-driving metabolic consequence"]},{"year":2013,"claim":"Extended SDHAF2 function beyond assembly by linking its loss to EMT and metastasis through GSK-3β/β-catenin signaling in lung cancer.","evidence":"SDH5 knockdown/knockout in lung cancer cells and mice, EMT marker analysis, xenograft metastasis model, and pathway analysis","pmids":["23983127"],"confidence":"Medium","gaps":["Mechanistic link between mitochondrial assembly role and GSK-3β signaling unclear","Direct molecular partners in the pathway not defined","Single lab"]},{"year":2019,"claim":"Implicated SDHAF2 in p53 turnover, with depletion stabilizing p53 to promote apoptosis and radiosensitivity in NSCLC.","evidence":"SDH5 KO mice and xenografts, immunoprecipitation, GST pulldown, in vitro ubiquitination, and apoptosis/DNA-damage assays","pmids":["31588224"],"confidence":"Medium","gaps":["Mechanism by which a mitochondrial assembly factor regulates p53 ubiquitination unresolved","Direct vs indirect interaction not fully separated","Single lab"]},{"year":2019,"claim":"Connected SDHAF2 loss to immune evasion by linking it to PD-L1 upregulation through GSK3β/β-catenin/ZEB1 signaling.","evidence":"SDH5 overexpression/knockdown in lung cancer cells, PD-L1 analysis in vitro and patient tissues, and pathway inhibitor experiments","pmids":["31741753"],"confidence":"Low","gaps":["Correlative pathway data with limited mechanistic depth","Not independently confirmed","Causal chain from SDHAF2 to ZEB1 not directly demonstrated"]},{"year":2024,"claim":"Placed SDHAF2 within a mitochondrial morphology–metabolism axis by showing its mitochondrial import requires Drp1-mediated fission, with consequences for complex II activity and insulin sensitivity.","evidence":"Drp1 knockdown in mouse muscle, mitochondrial fractionation, complex II assays, Sdhaf2 rescue, and metabolic phenotyping","pmids":["38569044"],"confidence":"Medium","gaps":["Mechanism coupling fission to SDHAF2 translocation undefined","Single lab","Generalizability beyond skeletal muscle untested"]},{"year":null,"claim":"How SDHAF2's canonical mitochondrial assembly role is mechanistically connected to its reported extramitochondrial functions (GSK-3β/β-catenin, p53, PD-L1) remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No defined molecular bridge between complex II assembly and cytosolic signaling","Alternative flavination mechanism unidentified","Mechanism converting SDH loss into paraganglioma initiation undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,3,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,5]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,2,6]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,6]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[0,2,5]}],"complexes":["succinate dehydrogenase (complex II)"],"partners":["SDHA","LONP1","TP53"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NX18","full_name":"Succinate dehydrogenase assembly factor 2, mitochondrial","aliases":[],"length_aa":166,"mass_kda":19.6,"function":"Plays an essential role in the assembly of succinate dehydrogenase (SDH), an enzyme complex (also referred to as respiratory complex II) that is a component of both the tricarboxylic acid (TCA) cycle and the mitochondrial electron transport chain, and which couples the oxidation of succinate to fumarate with the reduction of ubiquinone (coenzyme Q) to ubiquinol. Required for flavinylation (covalent attachment of FAD) of the flavoprotein subunit SDHA of the SDH catalytic dimer","subcellular_location":"Mitochondrion matrix","url":"https://www.uniprot.org/uniprotkb/Q9NX18/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/SDHAF2","classification":"Common Essential","n_dependent_lines":578,"n_total_lines":1208,"dependency_fraction":0.478476821192053},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SDHAF2","total_profiled":1310},"omim":[{"mim_id":"613019","title":"SUCCINATE DEHYDROGENASE COMPLEX ASSEMBLY FACTOR 2; SDHAF2","url":"https://www.omim.org/entry/613019"},{"mim_id":"605373","title":"PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 3; PPGL3","url":"https://www.omim.org/entry/605373"},{"mim_id":"601650","title":"PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 2; PPGL2","url":"https://www.omim.org/entry/601650"},{"mim_id":"171300","title":"PHEOCHROMOCYTOMA","url":"https://www.omim.org/entry/171300"},{"mim_id":"168000","title":"PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 1; PPGL1","url":"https://www.omim.org/entry/168000"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SDHAF2"},"hgnc":{"alias_symbol":["FLJ20487","SDH5"],"prev_symbol":["PGL2","C11orf79"]},"alphafold":{"accession":"Q9NX18","domains":[{"cath_id":"1.10.150.250","chopping":"64-147","consensus_level":"high","plddt":95.8768,"start":64,"end":147}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NX18","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NX18-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NX18-F1-predicted_aligned_error_v6.png","plddt_mean":83.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SDHAF2","jax_strain_url":"https://www.jax.org/strain/search?query=SDHAF2"},"sequence":{"accession":"Q9NX18","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NX18.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NX18/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NX18"}},"corpus_meta":[{"pmid":"19628817","id":"PMC_19628817","title":"SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma.","date":"2009","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19628817","citation_count":571,"is_preprint":false},{"pmid":"20071235","id":"PMC_20071235","title":"SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma.","date":"2010","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20071235","citation_count":212,"is_preprint":false},{"pmid":"28384794","id":"PMC_28384794","title":"Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.","date":"2017","source":"JAMA oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28384794","citation_count":152,"is_preprint":false},{"pmid":"21224366","id":"PMC_21224366","title":"SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21224366","citation_count":110,"is_preprint":false},{"pmid":"32887801","id":"PMC_32887801","title":"The roles of SDHAF2 and dicarboxylate in covalent flavinylation of SDHA, the human complex II flavoprotein.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32887801","citation_count":38,"is_preprint":false},{"pmid":"24414418","id":"PMC_24414418","title":"Mitochondrial matrix proteostasis is linked to hereditary paraganglioma: LON-mediated turnover of the human flavinylation factor SDH5 is regulated by its interaction with SDHA.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24414418","citation_count":38,"is_preprint":false},{"pmid":"24712571","id":"PMC_24712571","title":"Universal genetic screening uncovers a novel presentation of an SDHAF2 mutation.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24712571","citation_count":33,"is_preprint":false},{"pmid":"11728176","id":"PMC_11728176","title":"PGl2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency.","date":"2001","source":"Prostaglandins, leukotrienes, and essential fatty acids","url":"https://pubmed.ncbi.nlm.nih.gov/11728176","citation_count":30,"is_preprint":false},{"pmid":"23983127","id":"PMC_23983127","title":"Succinate dehydrogenase 5 (SDH5) regulates glycogen synthase kinase 3β-β-catenin-mediated lung cancer metastasis.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23983127","citation_count":29,"is_preprint":false},{"pmid":"23062074","id":"PMC_23062074","title":"Solution NMR structure of yeast succinate dehydrogenase flavinylation factor Sdh5 reveals a putative Sdh1 binding site.","date":"2012","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23062074","citation_count":25,"is_preprint":false},{"pmid":"20130071","id":"PMC_20130071","title":"Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas.","date":"2010","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20130071","citation_count":23,"is_preprint":false},{"pmid":"28099933","id":"PMC_28099933","title":"Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28099933","citation_count":20,"is_preprint":false},{"pmid":"27587393","id":"PMC_27587393","title":"The Assembly Factor SDHAF2 Is Dispensable for Flavination of the Catalytic Subunit of Mitochondrial Complex II in Breast Cancer Cells.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27587393","citation_count":18,"is_preprint":false},{"pmid":"38569044","id":"PMC_38569044","title":"Drp1 controls complex II assembly and skeletal muscle metabolism by Sdhaf2 action on mitochondria.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/38569044","citation_count":16,"is_preprint":false},{"pmid":"31741753","id":"PMC_31741753","title":"PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling.","date":"2019","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31741753","citation_count":15,"is_preprint":false},{"pmid":"31588224","id":"PMC_31588224","title":"SDH5 Depletion Enhances Radiosensitivity by Regulating p53: A New Method for Noninvasive Prediction of Radiotherapy Response.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31588224","citation_count":14,"is_preprint":false},{"pmid":"27296776","id":"PMC_27296776","title":"In-vitro, SDH5-dependent flavinylation of immobilized human respiratory complex II flavoprotein.","date":"2016","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/27296776","citation_count":10,"is_preprint":false},{"pmid":"20972721","id":"PMC_20972721","title":"Expression and somatic mutations of SDHAF2 (SDH5), a novel endocrine tumor suppressor gene in parathyroid tumors of primary hyperparathyroidism.","date":"2010","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/20972721","citation_count":7,"is_preprint":false},{"pmid":"24322175","id":"PMC_24322175","title":"Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas.","date":"2014","source":"World journal of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/24322175","citation_count":5,"is_preprint":false},{"pmid":"40079348","id":"PMC_40079348","title":"New Insights into the Clinical Characterization of SDHAF2-related Familial Paraganglioma Syndrome.","date":"2025","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40079348","citation_count":4,"is_preprint":false},{"pmid":"32133432","id":"PMC_32133432","title":"Tinnitus With Unexpected Spanish Roots: Head and Neck Paragangliomas Caused by SDHAF2 Mutation.","date":"2020","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/32133432","citation_count":4,"is_preprint":false},{"pmid":"32486318","id":"PMC_32486318","title":"Association of Common Genetic Variants in the CPSF7 and SDHAF2 Genes with Canine Idiopathic Pulmonary Fibrosis in the West Highland White Terrier.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32486318","citation_count":4,"is_preprint":false},{"pmid":"36326104","id":"PMC_36326104","title":"SDH5 down-regulation mitigates the damage of osteoporosis via inhibiting the MyD88/NF-κB signaling pathway.","date":"2022","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36326104","citation_count":1,"is_preprint":false},{"pmid":"41544268","id":"PMC_41544268","title":"The LARGE1 controls grain size by repressing the interaction between PGL2 and APG in rice.","date":"2026","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/41544268","citation_count":0,"is_preprint":false},{"pmid":"15562773","id":"PMC_15562773","title":"[Construction and identification of recombinant firefly luciferase reporter plasmid pGL2-PEPCK-Luc].","date":"2004","source":"Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae","url":"https://pubmed.ncbi.nlm.nih.gov/15562773","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.31.685748","title":"A novel genetic strategy to interrogate an unknown phenotypic modifier: an Sdhc KO-Robertsonian mouse with a semi-homologous chromosome develops papillary thyroid carcinoma-like tumours","date":"2025-11-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.31.685748","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15657,"output_tokens":3146,"usd":0.04708,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10636,"output_tokens":4150,"usd":0.078465,"stage2_stop_reason":"end_turn"},"total_usd":0.125545,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"Yeast and human SDH5 (SDHAF2) physically interact with the catalytic subunit of succinate dehydrogenase (Sdh1/SDHA) and are required for flavination (covalent attachment of FAD cofactor) of Sdh1/SDHA and for SDH-dependent respiration.\",\n      \"method\": \"Yeast genetics, mitochondrial proteomics, interaction studies, SDH activity assays, in vivo flavination assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction demonstrated, functional SDH activity and flavination assays in both yeast and human systems, replicated by multiple subsequent studies\",\n      \"pmids\": [\"19628817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NMR structure of yeast Sdh5 reveals a conserved surface region constituting a putative Sdh1-binding interface; point mutations in this region abolish covalent flavinylation of Sdh1. Sdh5 does not bind FAD in vitro, indicating it is not a simple FAD transporter.\",\n      \"method\": \"Solution NMR structure determination, site-directed mutagenesis, chemical shift perturbation measurements, in vivo flavinylation assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure plus mutagenesis and negative FAD-binding result in a single focused study\",\n      \"pmids\": [\"23062074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SDH5/SDHAF2 (G78R disease mutant) is imported and processed normally into human mitochondria but is rapidly degraded by the mitochondrial protease LONM (LON protease). Wild-type SDH5 is protected from LONM-mediated degradation through stable interaction with SDHA; the G78R mutant fails to form a stable complex with SDHA and is therefore degraded.\",\n      \"method\": \"Import-chase analysis in isolated human mitochondria (HeLa cells), in vitro LON protease degradation assay, LONM siRNA depletion, Blue Native PAGE complex analysis, SDHA siRNA depletion\",\n      \"journal\": \"FASEB Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (import assay, in vitro degradation, BN-PAGE, siRNA depletion) in a single focused study\",\n      \"pmids\": [\"24414418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In vitro flavinylation of recombinant human apo-SDHA is completely dependent on added SDH5 (SDHAF2), with a pH optimum of 6.5. FAD interacts noncovalently with SDHA in the absence of SDH5, suggesting SDH5 facilitates the covalent attachment step.\",\n      \"method\": \"In vitro flavinylation assay using recombinant His-tagged human apo-SDHA immobilized on Ni-IMAC resin with purified SDH5 in chemically defined medium\",\n      \"journal\": \"Archives of Biochemistry and Biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous in vitro reconstitution but single lab, single study\",\n      \"pmids\": [\"27296776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In human breast cancer cells, SDHAF2/SDH5 is dispensable for SDHA flavination: CRISPR-Cas9 nickase-mediated SDHAF2 knockout breast cancer cells retain flavinated SDHA, fully assembled and functional complex II, and normal mitochondrial respiration, demonstrating a cell-type-specific alternative flavination mechanism.\",\n      \"method\": \"CRISPR-Cas9 nickase knockout, complex II activity assay, mitochondrial respiration assay, SDHA flavination assay\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean KO with multiple functional readouts but single lab; contradicts yeast/other findings, suggesting context-dependency\",\n      \"pmids\": [\"27587393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"X-ray crystal structure of human SDHA in complex with SDHAF2 reveals that a small-molecule dicarboxylate acts as an essential cofactor that works in synergy with SDHAF2 to reorient the flavin and capping domains of SDHA, reorganize the active site, and adjust the pKa of SDHA-R451 to support covalent FAD attachment. Disease-associated SDHA mutations affect distinct conformational states assigned to assembly vs. catalysis.\",\n      \"method\": \"X-ray crystallography of human SDHA–SDHAF2 complex, biochemical reconstitution, disease mutant analysis, identification of dicarboxylate cofactor\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with biochemical reconstitution and mutant analysis in a single rigorous study\",\n      \"pmids\": [\"32887801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Drp1-mediated mitochondrial fission is required for mitochondrial translocation of SDHAF2 in skeletal muscle; knockdown of Drp1 reduces SDHAF2 mitochondrial import, leading to impaired complex II assembly and activity. Restoration of SDHAF2 in Drp1-KD myocytes normalizes complex II activity, lipid oxidation, and insulin sensitivity, placing SDHAF2 downstream of Drp1 in a mitochondrial morphology–metabolism axis.\",\n      \"method\": \"Drp1 knockdown in mouse muscle (in vivo), mitochondrial fractionation, complex II assembly and activity assays, Sdhaf2 rescue experiments in myocytes, metabolic phenotyping (fatty acid oxidation, insulin action)\",\n      \"journal\": \"Science Advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with rescue, multiple functional readouts; single lab\",\n      \"pmids\": [\"38569044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Loss of SDH5 (SDHAF2) in lung cancer cells and mice initiates epithelial-mesenchymal transition (EMT), evidenced by repression of E-cadherin and upregulation of vimentin, and promotes lymph node metastasis in a human lung xenograft model. SDH5 modulates EMT by regulating the GSK-3β–β-catenin signaling pathway.\",\n      \"method\": \"SDH5 knockdown/knockout in lung cancer cell lines and mice, E-cadherin/vimentin expression, human xenograft-mouse metastasis model, GSK-3β/β-catenin pathway analysis\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD/KO with defined cellular and in vivo phenotypes plus pathway analysis; single lab\",\n      \"pmids\": [\"23983127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SDH5 (SDHAF2) regulates PD-L1 expression in lung cancer via the GSK3β/β-catenin/ZEB1 signaling axis; SDH5 loss increases PD-L1 expression through this pathway.\",\n      \"method\": \"SDH5 overexpression/knockdown in lung cancer cells, PD-L1 expression analysis in vitro and patient tissues, pathway inhibitor experiments (GSK3β/β-catenin/ZEB1)\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, signaling pathway correlation with limited mechanistic depth reported in abstract\",\n      \"pmids\": [\"31741753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SDH5 (SDHAF2) depletion inhibits p53 degradation via the ubiquitin/proteasome pathway, promoting apoptosis and enhancing radiosensitivity in non-small cell lung cancer. SDH5 interaction with p53 was detected by immunoprecipitation and GST pulldown, and SDH5-dependent polyubiquitination of p53 was demonstrated by in vitro ubiquitination assay.\",\n      \"method\": \"SDH5 KO mice and human xenograft model, immunoprecipitation, GST pulldown, in vitro ubiquitination assay, apoptosis/DNA damage assays\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro ubiquitination assay plus pulldown and in vivo model; single lab, single study\",\n      \"pmids\": [\"31588224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The SDHAF2 Gly78Arg (G78R) mutation is pathogenic for hereditary paraganglioma; identification of a second unrelated family with the same mutation confirms Gly78 as a critical residue for SDHAF2 function.\",\n      \"method\": \"Germline mutation analysis, haplotype analysis in familial paraganglioma kindreds\",\n      \"journal\": \"The Lancet Oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — genetic evidence from two families confirms functional importance of Gly78, but no direct biochemical mechanism reported in this paper\",\n      \"pmids\": [\"20071235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Loss of the entire maternal copy of chromosome 11 occurs in 89% of SDHAF2-related paragangliomas, always affecting the maternal allele, consistent with the parent-of-origin imprinting effect and providing a mechanistic basis for the paternal transmission requirement in SDHAF2 disease.\",\n      \"method\": \"FISH, microsatellite marker analysis, SNP array analysis, methylation analysis of imprinted DMRs (H19-DMR, KvDMR) in SDHAF2-related tumor specimens\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal genomic methods on tumor specimens; single study but mechanistically informative for imprinting mechanism\",\n      \"pmids\": [\"28099933\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SDHAF2 (SDH5) is a mitochondrial assembly factor that physically interacts with the SDHA flavoprotein subunit of complex II; together with a dicarboxylate cofactor (as revealed by the crystal structure of the human SDHA–SDHAF2 complex), it reorients the SDHA active site and lowers the pKa of SDHA-R451 to enable covalent attachment of FAD—a process that can be fully reconstituted in vitro—while SDHAF2 itself is protected from LON protease degradation only when stably bound to SDHA, explaining why the disease-causing G78R mutant is rapidly turned over. Beyond its canonical assembly role, SDHAF2 has been reported to modulate GSK-3β/β-catenin signaling (affecting EMT and PD-L1 expression in lung cancer) and to regulate p53 stability, and its mitochondrial import depends on Drp1-mediated fission in skeletal muscle; maternal-allele loss of chromosome 11 underpins the parent-of-origin tumor risk conferred by SDHAF2 mutations.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SDHAF2 (SDH5) is a mitochondrial assembly factor for succinate dehydrogenase (complex II) that physically interacts with the catalytic flavoprotein subunit SDHA and is required for its covalent flavinylation and SDH-dependent respiration [#0]. SDHAF2 does not itself bind FAD; instead, a conserved surface region forms the SDHA-binding interface, and mutations there abolish flavinylation, establishing SDHAF2 as a catalytic chaperone rather than a simple FAD transporter [#1]. In vitro reconstitution shows that flavinylation of recombinant apo-SDHA is fully dependent on SDHAF2 with an acidic pH optimum, acting at the covalent attachment step [#3], and the human SDHA–SDHAF2 crystal structure resolves the mechanism: a small-molecule dicarboxylate cofactor works in synergy with SDHAF2 to reorient the SDHA flavin and capping domains and adjust the pKa of SDHA-R451 to enable covalent FAD attachment [#5]. SDHAF2 stability is coupled to this interaction—it is protected from LON protease degradation only when stably bound to SDHA, explaining the rapid turnover of the disease-associated G78R mutant, which fails to form a stable complex [#2]. This role is context-dependent: SDHAF2 is dispensable for SDHA flavination in certain breast cancer cells, which retain functional complex II via an alternative mechanism [#4]. Germline SDHAF2 mutation (G78R) causes hereditary paraganglioma, with the parent-of-origin tumor risk explained by maternal-allele loss of chromosome 11 in tumors [#10, #11]. Beyond assembly, reported extramitochondrial functions include modulation of GSK-3β/β-catenin signaling driving EMT and metastasis [#7] and regulation of p53 stability via the ubiquitin/proteasome pathway [#9].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Established the existence and core function of SDHAF2 by showing it is a dedicated interactor of the SDH catalytic subunit required for FAD attachment, defining a previously unrecognized assembly step for complex II.\",\n      \"evidence\": \"Yeast genetics, mitochondrial proteomics, and in vivo flavination/SDH activity assays in yeast and human systems\",\n      \"pmids\": [\"19628817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Did not resolve whether SDHAF2 acts catalytically or as an FAD carrier\",\n        \"No structural basis for the SDHA interface\",\n        \"Conservation of mechanism across cell types untested\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined SDHAF2 as a catalytic chaperone rather than an FAD transporter by mapping the SDHA-binding surface and demonstrating it does not bind FAD itself.\",\n      \"evidence\": \"Solution NMR structure of yeast Sdh5, chemical shift perturbation, site-directed mutagenesis, and in vivo flavinylation assays\",\n      \"pmids\": [\"23062074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Did not show how SDHAF2 promotes covalent attachment mechanistically\",\n        \"Human SDHAF2 structure not determined here\",\n        \"No co-structure with SDHA\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked SDHAF2 to human disease by establishing the G78R mutation as pathogenic for hereditary paraganglioma, identifying Gly78 as a functionally critical residue.\",\n      \"evidence\": \"Germline mutation and haplotype analysis in two familial paraganglioma kindreds\",\n      \"pmids\": [\"20071235\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No direct biochemical mechanism for G78R reported in this study\",\n        \"Parent-of-origin transmission unexplained at the molecular level\",\n        \"Tissue specificity of tumorigenesis unaddressed\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Explained why the G78R mutant is loss-of-function by showing SDHAF2 stability depends on SDHA binding, with unbound or mutant protein cleared by LON protease.\",\n      \"evidence\": \"Import-chase in isolated human mitochondria, in vitro LON degradation, BN-PAGE, and LONM/SDHA siRNA depletion\",\n      \"pmids\": [\"24414418\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural reason for G78R destabilization not defined\",\n        \"Did not address whether LON regulates SDHAF2 levels physiologically\",\n        \"In vivo relevance to paraganglioma tissue untested\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated by full in vitro reconstitution that SDHAF2 is strictly required for covalent flavinylation of apo-SDHA, acting at the attachment step under acidic conditions.\",\n      \"evidence\": \"In vitro flavinylation of recombinant immobilized apo-SDHA with purified SDH5 in defined medium\",\n      \"pmids\": [\"27296776\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab reconstitution\",\n        \"Did not identify the chemical role of accessory cofactors\",\n        \"Catalytic mechanism inferred, not visualized\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed context dependence of SDHAF2 by showing it is dispensable for SDHA flavination in breast cancer cells, implying an alternative flavination route.\",\n      \"evidence\": \"CRISPR-Cas9 nickase knockout with complex II activity, respiration, and SDHA flavination assays\",\n      \"pmids\": [\"27587393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity of the alternative flavination mechanism unknown\",\n        \"Single cell-type/single lab observation\",\n        \"Reconciliation with strict in vitro dependence unresolved\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved the molecular mechanism of SDHAF2-assisted flavinylation by capturing the human SDHA–SDHAF2 complex and identifying a dicarboxylate cofactor that, with SDHAF2, reorganizes the active site and tunes SDHA-R451 pKa.\",\n      \"evidence\": \"X-ray crystallography of the human SDHA–SDHAF2 complex with biochemical reconstitution and disease-mutant analysis\",\n      \"pmids\": [\"32887801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Dynamics of cofactor entry/exit not captured\",\n        \"Does not explain alternative flavination in some cancer cells\",\n        \"Extramitochondrial functions not addressed\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided the molecular basis for parent-of-origin tumor risk by showing maternal chromosome 11 loss in most SDHAF2-related paragangliomas, consistent with imprinting.\",\n      \"evidence\": \"FISH, microsatellite and SNP array analysis, and DMR methylation analysis of tumor specimens\",\n      \"pmids\": [\"28099933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism linking SDH loss to paraganglioma initiation not defined\",\n        \"Single study cohort\",\n        \"Does not establish the tumor-driving metabolic consequence\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended SDHAF2 function beyond assembly by linking its loss to EMT and metastasis through GSK-3β/β-catenin signaling in lung cancer.\",\n      \"evidence\": \"SDH5 knockdown/knockout in lung cancer cells and mice, EMT marker analysis, xenograft metastasis model, and pathway analysis\",\n      \"pmids\": [\"23983127\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanistic link between mitochondrial assembly role and GSK-3β signaling unclear\",\n        \"Direct molecular partners in the pathway not defined\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Implicated SDHAF2 in p53 turnover, with depletion stabilizing p53 to promote apoptosis and radiosensitivity in NSCLC.\",\n      \"evidence\": \"SDH5 KO mice and xenografts, immunoprecipitation, GST pulldown, in vitro ubiquitination, and apoptosis/DNA-damage assays\",\n      \"pmids\": [\"31588224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which a mitochondrial assembly factor regulates p53 ubiquitination unresolved\",\n        \"Direct vs indirect interaction not fully separated\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected SDHAF2 loss to immune evasion by linking it to PD-L1 upregulation through GSK3β/β-catenin/ZEB1 signaling.\",\n      \"evidence\": \"SDH5 overexpression/knockdown in lung cancer cells, PD-L1 analysis in vitro and patient tissues, and pathway inhibitor experiments\",\n      \"pmids\": [\"31741753\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Correlative pathway data with limited mechanistic depth\",\n        \"Not independently confirmed\",\n        \"Causal chain from SDHAF2 to ZEB1 not directly demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed SDHAF2 within a mitochondrial morphology–metabolism axis by showing its mitochondrial import requires Drp1-mediated fission, with consequences for complex II activity and insulin sensitivity.\",\n      \"evidence\": \"Drp1 knockdown in mouse muscle, mitochondrial fractionation, complex II assays, Sdhaf2 rescue, and metabolic phenotyping\",\n      \"pmids\": [\"38569044\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism coupling fission to SDHAF2 translocation undefined\",\n        \"Single lab\",\n        \"Generalizability beyond skeletal muscle untested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SDHAF2's canonical mitochondrial assembly role is mechanistically connected to its reported extramitochondrial functions (GSK-3β/β-catenin, p53, PD-L1) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No defined molecular bridge between complex II assembly and cytosolic signaling\",\n        \"Alternative flavination mechanism unidentified\",\n        \"Mechanism converting SDH loss into paraganglioma initiation undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 2, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [0, 2, 5]}\n    ],\n    \"complexes\": [\n      \"succinate dehydrogenase (complex II)\"\n    ],\n    \"partners\": [\n      \"SDHA\",\n      \"LONP1\",\n      \"TP53\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}